You choose, we deliver
If you are interested in this story, you might be interested in others from The Journal Gazette. Go to www.journalgazette.net/newsletter and pick the subjects you care most about. We'll deliver your customized daily news report at 3 a.m. Fort Wayne time, right to your email.

Health

  • Combined spinning, yoga class works body
    It seems as though we are always struggling for balance in our lives. Work or play? Spend or save? Eat that doughnut or save those calories? The same is true for our fitness regimens.
  • Check sodium in frozen meals
    Calories, fat and, heck, maybe even carbohydrates might be among the things you look for on a nutrition label.But have you stopped to look at the sodium?
  • Psychiatric drug shows promise in cancer fight
    A well-known drug for treating schizophrenia may be a cancer killer, too. In lab studies, the drug thioridazine wiped out a precursor to leukemia cells without harming normal cells.
Advertisement
Roche
Avastin

Doctors, cancer patients warned about fake Avastin

WASHINGTON – The maker of the best-selling cancer drug Avastin is warning doctors and patients about counterfeit vials of the product distributed in the U.S.

Roche’s Genentech unit said the fake products do not contain the key ingredient in Avastin, which is used to treat cancers of the colon, lung, kidney and brain.

Doctors who suspect they have received counterfeit drug should contact the Food and Drug Administration’s criminal unit or Roche quality assurance department. The company said any patient taking Avastin who experiences side effects should contact their doctor immediately.

The company said the counterfeit products do not have Genentech printed on the packaging, which appears on all FDA-approved packages of the drug.

Additionally, real Avastin contains a six-digit lot number with no letters. All the text on the product’s packaging should be in English.

The company believes drugs labeled with the following lot numbers might be fake: B86017, B6011 and B6010.

Avastin is a widely-prescribed cancer therapy that works by choking off the blood supply that feeds tumors, the first drug of its kind approved by the FDA.

The injectable drug generates about $6 billion per year for the Swiss drugmaker Roche, and in 2010 it was the 14th best-selling drug in the U.S., according to data tracking firm IMS Health.